

DENOMINAZIONE FARMACO	PROCEDURA	ATC	PRINCIPIO ATTIVO	TITOLARE	PARERE CHMP	DECISIONE COMMISSIONE	DATA GUUE	data CTS	AIC	Confezione
Mimpara	EMEA/H/C/000570/X/0055/G	H05BX01	Cinacalcet	Amgen Europe B.V.	22-giu-17	28-ago-17	29-set-17	09-ott-17	036598136	13
Mimpara	EMEA/H/C/000570/X/0055/G	H05BX01	Cinacalcet	Amgen Europe B.V.	22-giu-17	28-ago-17	29-set-17	09-ott-17	036598148	14
Mimpara	EMEA/H/C/000570/X/0055/G	H05BX01	Cinacalcet	Amgen Europe B.V.	22-giu-17	28-ago-17	29-set-17	09-ott-17	036598151	15
Constella	EMEA/H/C/2490/IB/0027	A06AX04	linaclootide	Allergan Pharmaceuticals International Limited	25-ago-16	11-apr-17	30-mag-17	09-ott-17	042491050	5
Imraldi	EMEA/H/C/4279	L04AB04	adalimumab	Samsung Bioepis UK Limited	22-giu-17	24-ago-17	29-set-17	09-ott-17	045616012	1
Imraldi	EMEA/H/C/4279	L04AB04	adalimumab	Samsung Bioepis UK Limited	22-giu-17	24-ago-17	29-set-17	09-ott-17	045616024	2
Imraldi	EMEA/H/C/4279	L04AB04	adalimumab	Samsung Bioepis UK Limited	22-giu-17	24-ago-17	29-set-17	09-ott-17	045616036	3
Imraldi	EMEA/H/C/4279	L04AB04	adalimumab	Samsung Bioepis UK Limited	22-giu-17	24-ago-17	29-set-17	09-ott-17	045616048	4
Nitisinone MendeliKABS	EMEA/H/C/4281	A16AX04	nitisinone	MendeliKABS Europe Limited	22-giu-17	24-ago-17	29-set-17	09-ott-17	045620010	1
Nitisinone MendeliKABS	EMEA/H/C/4281	A16AX04	nitisinone	MendeliKABS Europe Limited	22-giu-17	24-ago-17	29-set-17	09-ott-17	045620022	2
Nitisinone MendeliKABS	EMEA/H/C/4281	A16AX04	nitisinone	MendeliKABS Europe Limited	22-giu-17	24-ago-17	29-set-17	09-ott-17	045620034	3
Fotivda	EMEA/H/C/4131	L01XE34	tivozanib	EUSA Pharma (UK) Limited	22-giu-17	24-ago-17	29-set-17	09-ott-17	045619018	1
Fotivda	EMEA/H/C/4131	L01XE34	tivozanib	EUSA Pharma (UK) Limited	22-giu-17	24-ago-17	29-set-17	09-ott-17	045619020	2
MAVENCLAD	EMEA/H/C/4230	L01BB04	cladribine	Merck Serono Europe Limited	22-giu-17	22-ago-17	29-set-17	09-ott-17	045615010	1
MAVENCLAD	EMEA/H/C/4230	L01BB04	cladribine	Merck Serono Europe Limited	22-giu-17	22-ago-17	29-set-17	09-ott-17	045615022	2
MAVENCLAD	EMEA/H/C/4230	L01BB04	cladribine	Merck Serono Europe Limited	22-giu-17	22-ago-17	29-set-17	09-ott-17	045615034	3
MAVENCLAD	EMEA/H/C/4230	L01BB04	cladribine	Merck Serono Europe Limited	22-giu-17	22-ago-17	29-set-17	09-ott-17	045615046	4
MAVENCLAD	EMEA/H/C/4230	L01BB04	cladribine	Merck Serono Europe Limited	22-giu-17	22-ago-17	29-set-17	09-ott-17	045615059	5
MAVENCLAD	EMEA/H/C/4230	L01BB04	cladribine	Merck Serono Europe Limited	22-giu-17	22-ago-17	29-set-17	09-ott-17	045615061	6
Kisqali	EMEA/H/C/004213	L01XE42	ribociclib	Novartis Europharm Limited	22-giu-17	22-ago-17	29-set-17	09-ott-17	045618016	1
Kisqali	EMEA/H/C/004213	L01XE42	ribociclib	Novartis Europharm Limited	22-giu-17	22-ago-17	29-set-17	09-ott-17	045618028	2
Kisqali	EMEA/H/C/004213	L01XE42	ribociclib	Novartis Europharm Limited	22-giu-17	22-ago-17	29-set-17	09-ott-17	045618030	3
Kisqali	EMEA/H/C/004213	L01XE42	ribociclib	Novartis Europharm Limited	22-giu-17	22-ago-17	29-set-17	09-ott-17	045618042	4
Kisqali	EMEA/H/C/004213	L01XE42	ribociclib	Novartis Europharm Limited	22-giu-17	22-ago-17	29-set-17	09-ott-17	045618055	5
Kisqali	EMEA/H/C/004213	L01XE42	ribociclib	Novartis Europharm Limited	22-giu-17	22-ago-17	29-set-17	09-ott-17	045618067	6
Kisqali	EMEA/H/C/004213	L01XE42	ribociclib	Novartis Europharm Limited	22-giu-17	22-ago-17	29-set-17	09-ott-17	045618079	7
Kisqali	EMEA/H/C/004213	L01XE42	ribociclib	Novartis Europharm Limited	22-giu-17	22-ago-17	29-set-17	09-ott-17	045618081	8
Kisqali	EMEA/H/C/004213	L01XE42	ribociclib	Novartis Europharm Limited	22-giu-17	22-ago-17	29-set-17	09-ott-17	045618093	9
Kisqali	EMEA/H/C/004213	L01XE42	ribociclib	Novartis Europharm Limited	22-giu-17	22-ago-17	29-set-17	09-ott-17	045618105	10
Kisqali	EMEA/H/C/004213	L01XE42	ribociclib	Novartis Europharm Limited	22-giu-17	22-ago-17	29-set-17	09-ott-17	045618117	11
Kisqali	EMEA/H/C/004213	L01XE42	ribociclib	Novartis Europharm Limited	22-giu-17	22-ago-17	29-set-17	09-ott-17	045618129	12
Nordimet	EMEA/H/C/3983/IB/02/G	L01BA01	methotrexate	Nordic Group B.V.	11-ott-16	07-ago-17	29-set-17	09-ott-17	045033091	9
Nordimet	EMEA/H/C/3983/IB/02/G	L01BA01	methotrexate	Nordic Group B.V.	11-ott-16	07-ago-17	29-set-17	09-ott-17	045033103	10
Nordimet	EMEA/H/C/3983/IB/02/G	L01BA01	methotrexate	Nordic Group B.V.	11-ott-16	07-ago-17	29-set-17	09-ott-17	045033115	11
Nordimet	EMEA/H/C/3983/IB/02/G	L01BA01	methotrexate	Nordic Group B.V.	11-ott-16	07-ago-17	29-set-17	09-ott-17	045033127	12
Nordimet	EMEA/H/C/3983/IB/02/G	L01BA01	methotrexate	Nordic Group B.V.	11-ott-16	07-ago-17	29-set-17	09-ott-17	045033139	13
Nordimet	EMEA/H/C/3983/IB/02/G	L01BA01	methotrexate	Nordic Group B.V.	11-ott-16	07-ago-17	29-set-17	09-ott-17	045033141	14
Nordimet	EMEA/H/C/3983/IB/02/G	L01BA01	methotrexate	Nordic Group B.V.	11-ott-16	07-ago-17	29-set-17	09-ott-17	045033154	15
Nordimet	EMEA/H/C/3983/IB/02/G	L01BA01	methotrexate	Nordic Group B.V.	11-ott-16	07-ago-17	29-set-17	09-ott-17	045033166	16
Nordimet	EMEA/H/C/3983/IB/02/G	L01BA01	methotrexate	Nordic Group B.V.	11-ott-16	07-ago-17	29-set-17	09-ott-17	045033178	17
Nordimet	EMEA/H/C/3983/IB/02/G	L01BA01	methotrexate	Nordic Group B.V.	11-ott-16	07-ago-17	29-set-17	09-ott-17	045033180	18
Nordimet	EMEA/H/C/3983/IB/02/G	L01BA01	methotrexate	Nordic Group B.V.	11-ott-16	07-ago-17	29-set-17	09-ott-17	045033192	19
Nordimet	EMEA/H/C/3983/IB/02/G	L01BA01	methotrexate	Nordic Group B.V.	11-ott-16	07-ago-17	29-set-17	09-ott-17	045033204	20
Nordimet	EMEA/H/C/3983/IB/02/G	L01BA01	methotrexate	Nordic Group B.V.	11-ott-16	07-ago-17	29-set-17	09-ott-17	045033216	21
Nordimet	EMEA/H/C/3983/IB/02/G	L01BA01	methotrexate	Nordic Group B.V.	11-ott-16	07-ago-17	29-set-17	09-ott-17	045033228	22
Nordimet	EMEA/H/C/3983/IB/02/G	L01BA01	methotrexate	Nordic Group B.V.	11-ott-16	07-ago-17	29-set-17	09-ott-17	045033230	23
Nordimet	EMEA/H/C/3983/IB/02/G	L01BA01	methotrexate	Nordic Group B.V.	11-ott-16	07-ago-17	29-set-17	09-ott-17	045033242	24

La responsabilità di qualsiasi onere e/o attività che l' Azienda affronti utilizzando i codici AIC attribuiti alle confezioni (e inseriti nella Banca Dati del Farmaco-AIFA) precedentemente alla pubblicazione sulla Gazzetta Ufficiale della autorizzazione AIFA all' immissione in commercio del medicinale, è totalmente a carico dell' Azienda stessa. L' ufficialità dei codici AIC è subordinata alla pubblicazione degli stessi sulla Gazzetta Ufficiale, fino ad allora sono possibili, seppure improbabili, sue variazioni.